<DOC>
	<DOC>NCT01542424</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to investigate efficacy and safety of NovoMix速 30 (biphasic insulin aspart 30) or Levemir速 (insulin detemir) in subjects with type 1 or 2 diabetes mellitus.</brief_summary>
	<brief_title>An Observational Study in Patients Using NovoMix速 30 or Levemir速 for Treatment of Type 1 or Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 1</mesh_term>
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<criteria>Macedonian people with diabetes mellitus (Type 1 or Type 2)</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>